Log in to save to my catalogue

IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (O...

IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (O...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2568459085

IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD)

About this item

Full title

IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD)

Publisher

London: BMJ Publishing Group LTD

Journal title

Gut, 2021-09, Vol.70 (Suppl 2), p.A76-A77

Language

English

Formats

Publication information

Publisher

London: BMJ Publishing Group LTD

More information

Scope and Contents

Contents

BackgroundWe have previously shown in renally impaired (RI) CHB patients, including those with ESRD on HD, that switching to TAF from TDF and/or other OAVs maintains high rates of viral suppression with stable bone and renal safety parameters at Week 48. Here we present the final Week 96 results.MethodsIn this study, virally suppressed CHB patients...

Alternative Titles

Full title

IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD)

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2568459085

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2568459085

Other Identifiers

ISSN

0017-5749

E-ISSN

1468-3288

DOI

10.1136/gutjnl-2021-IDDF.80

How to access this item